Atrial fibrillation (AF)

Diagnostic and therapeutic approach

Vernakalant (Brinavess)


Available only in injectable


3 mg/kg of body weight in 10 minutes.

If no conversion after 15 minutes, add 2mg/kg in 10 minutes.


  • Hypersensitivity to vernakalant hydrochloride (Brinavess) or to any of the excipients.
  • Hemodynamic instability.
  • Acute or chronic heart failure of NYHA class III or IV.
  • Severe aortic stenosis.
  • Systolic blood pressure <100 mmHg.
  • QT interval prolongation.
  • Severe bradycardia, sinus node dysfunction.
  • AV block of 2nd and 3rd degree.
  • Administration of intravenous antiarrhythmics (class I and class III) within 4 hours before or after administration of vernakalant (Brinavess).
  • Acute Coronary Syndrome.